Healthcare AI Exits Pilot Phase, Enters Production Deployment

About this update from Ventripoint Diagnostics Ltd.

[{"type":"text","content":"Healthcare AI Exits Pilot Phase, Enters Production DeploymentIssued on behalf of VentriPoint Diagnostics Ltd.\n\n\n\n VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) --\n \n\n Equity-Insider.com\n \n\n\n News Commentary\n \n – Healthcare organizations are setting the pace for enterprise AI adoption as operational automation moves from experimentation to production scale across hospital systems\n \n [1]\n \n . The shift reflects a fundamental change in how healthcare leaders view AI technology, with deployment projected to expand the global healthcare AI market from $17.2 billion in 2025 to $77.2 billion by 2035\n \n [2]\n \n . Five publicly traded companies are positioned at the intersection of this operational transformation, delivering infrastructure that turns AI capabilities into measurable workflow improvements and financial returns:\n \n VentriPoint Diagnostics\n \n (TSXV: VPT) (OTCPK: VPTDF),\n \n Doximity, Inc.\n \n (NYSE: DOCS),\n \n Oscar Health, Inc.\n \n (NYSE: OSCR),\n \n Cognizant Technology Solutions Corporation\n \n (NASDAQ: CTSH), and\n \n Certara, Inc.\n \n (NASDAQ: CERT).\n \n\n Industry data shows 80% of hospitals now deploy AI for operational efficiency and patient care, marking a decisive break from the pilot project era that dominated 2023 and early 2024\n \n [3]\n \n . Healthcare systems are prioritizing agentic AI platforms that automate complex workflows across clinical documentation, administrative processes, and enterprise systems, creating conditions where early infrastructure providers can establish durable competitive positions before the market matures\n \n [4]\n \n .\n \n\n\n Ventripoint Diagnostics\n \n (TSXV: VPT) (OTCPK: VPTDF) just announced a partnership with\n \n Nisg\n \n\n ̱\n \n\n a'a Valley Health Authority\n \n that establishes a global model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration centers on\n \n Ventripoint's\n \n VMS+ system, which transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy. This technology enables precise cardiac assessments at the point of care, reducing costs and eliminating the need for time-consuming MRI scans.\n \n\n The model follows a hub-and-spoke design where a central hub with advanced cardiac capabilities supports connected sites in smaller, r...

More updates from Ventripoint Diagnostics Ltd.